Effect of perioperative use of parecoxib on chronic post-surgical pain in elderly patients after hepatectomy: a prospective randomized controlled study

Abstract Background Chronic post-surgical pain (CPSP) has a negative impact on the recovery, quality of life, and physical functioning of elderly patients. This study aimed to test the superiority of parecoxib vs. placebo in preventing chronic post-hepatectomy pain in elderly patients under combined...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaodong Ge (Author), Yan Pan (Author), Danfeng Jin (Author), Ying Wang (Author), Shengjin Ge (Author)
Format: Book
Published: BMC, 2021-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_df2f8ea55ed848bebfd23ef3a51cdd2e
042 |a dc 
100 1 0 |a Xiaodong Ge  |e author 
700 1 0 |a Yan Pan  |e author 
700 1 0 |a Danfeng Jin  |e author 
700 1 0 |a Ying Wang  |e author 
700 1 0 |a Shengjin Ge  |e author 
245 0 0 |a Effect of perioperative use of parecoxib on chronic post-surgical pain in elderly patients after hepatectomy: a prospective randomized controlled study 
260 |b BMC,   |c 2021-06-01T00:00:00Z. 
500 |a 10.1186/s40360-021-00501-1 
500 |a 2050-6511 
520 |a Abstract Background Chronic post-surgical pain (CPSP) has a negative impact on the recovery, quality of life, and physical functioning of elderly patients. This study aimed to test the superiority of parecoxib vs. placebo in preventing chronic post-hepatectomy pain in elderly patients under combined general-epidural anesthesia. Methods A total of 105 elderly patients undergoing hepatectomy under combined general-epidural anesthesia were randomized into the parecoxib or placebo group. The primary outcome was the proportion of patients with CPSP 3 months postoperatively. The secondary outcomes included the Short-Form McGill Pain Questionnaire score in CPSP-positive responders, acute pain intensity, postoperative analgesic demand, inflammatory markers change, and postoperative complications within 28 days. Results The parecoxib group provided a non-significant absolute 9.1% reduction in the rate of CPSP compared to the placebo group (P = 0.34). The average chronic pain visual analog scale in the parecoxib group was lower than that in the placebo group (P = 0.04). Significantly less moderate-to-severe acute pain at rest (P = 0.04) and with coughing (P < 0.001), less patient-controlled epidural analgesia (PCEA) consumption (P = 0.01), and less rescue analgesia (P < 0.001) were observed in the parecoxib group compared to the placebo group. Furthermore, no between-group difference was observed in inflammatory markers (P > 0.05) and postoperative complications (P = 0.65). Conclusions Parecoxib reduced the prevalence of CPSP in elderly patients after hepatectomy under combined general-epidural anesthesia from 44.4 to 35.3% with no statistical significance. Moreover, significantly alleviated CPSP intensity and improved acute pain management were observed. Trial registration This study was retrospectively registered in the Chinese Clinical Trial Registry (URL: http://www.chictr.org.cn/edit.aspx?pid=56961&htm=4 ) on August 3, 2020 ( ChiCTR-2,000,035,198 ). 
546 |a EN 
690 |a Parecoxib 
690 |a Chronic post-surgical pain 
690 |a Elderly 
690 |a Hepatectomy 
690 |a Multimodal analgesia 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Toxicology. Poisons 
690 |a RA1190-1270 
655 7 |a article  |2 local 
786 0 |n BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-12 (2021) 
787 0 |n https://doi.org/10.1186/s40360-021-00501-1 
787 0 |n https://doaj.org/toc/2050-6511 
856 4 1 |u https://doaj.org/article/df2f8ea55ed848bebfd23ef3a51cdd2e  |z Connect to this object online.